Literature DB >> 23200297

Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system.

L A Carvalho1, J P Torre, A S Papadopoulos, L Poon, M F Juruena, K Markopoulou, A J Cleare, C M Pariante.   

Abstract

Despite the evidence of an association between depression and increased inflammatory markers, still little is known in relation to the most severe cases of the disorder i.e., those who fail to respond to antidepressants. We have assessed the cytokine profile and cortisol levels in 21 healthy controls (HC) and 19 medicated patients with depression with treatment-resistance (TRD) moderately ill. As an initial exploratory analysis, we have also related cytokine profile to the patient's clinical treatment outcome after an inpatient admission. Cytokine profile was measured in the serum by the Cytokine Array I kit (Randox). Plasma cortisol was carried out using a commercially available for the IMMULITE system. When compared to healthy controls, depressed patients had higher levels of cortisol, IL-6, IL-10, but lower levels of IL-4 and VEGF. Our exploratory analysis showed subjects who did not go on to respond to the inpatient admission treatment package had lower levels of MCP-1, and a trend toward lower levels of VEGF. Taking together, these data suggest that lack of clinical therapeutic benefit of antidepressants is associated with overall activation of the inflammatory system.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23200297     DOI: 10.1016/j.jad.2012.10.036

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  58 in total

Review 1.  Inflammation: depression fans the flames and feasts on the heat.

Authors:  Janice K Kiecolt-Glaser; Heather M Derry; Christopher P Fagundes
Journal:  Am J Psychiatry       Date:  2015-09-11       Impact factor: 18.112

Review 2.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

Review 3.  Inflammatory cytokine-associated depression.

Authors:  Francis E Lotrich
Journal:  Brain Res       Date:  2014-07-05       Impact factor: 3.252

Review 4.  Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies.

Authors:  Ajaykumar N Sharma; Bruno Fernando Borges da Costa e Silva; Jair C Soares; André F Carvalho; Joao Quevedo
Journal:  J Affect Disord       Date:  2016-03-02       Impact factor: 4.839

Review 5.  Rodent models of treatment-resistant depression.

Authors:  Barbara J Caldarone; Venetia Zachariou; Sarah L King
Journal:  Eur J Pharmacol       Date:  2014-11-21       Impact factor: 4.432

Review 6.  Role of neuro-immunological factors in the pathophysiology of mood disorders.

Authors:  Anindya Bhattacharya; Noel C Derecki; Timothy W Lovenberg; Wayne C Drevets
Journal:  Psychopharmacology (Berl)       Date:  2016-01-23       Impact factor: 4.530

Review 7.  Backing into the future: pharmacological approaches to the management of resistant depression.

Authors:  P J Cowen
Journal:  Psychol Med       Date:  2017-08-25       Impact factor: 7.723

Review 8.  Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment.

Authors:  Golam M Khandaker; Lesley Cousins; Julia Deakin; Belinda R Lennox; Robert Yolken; Peter B Jones
Journal:  Lancet Psychiatry       Date:  2015-02-25       Impact factor: 27.083

Review 9.  New Pharmacological Interventions in Bipolar Disorder.

Authors:  Mario F Juruena; Luke A Jelen; Allan H Young; Anthony J Cleare
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 10.  Targeting the CCL2-CCR2 axis in depressive disorders.

Authors:  Katarzyna Curzytek; Monika Leśkiewicz
Journal:  Pharmacol Rep       Date:  2021-05-24       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.